Rol de los antiespasmódicos en el manejo del síndrome de intestino irritable


  • Valeria Atenea Costa Hospital Universitario San Ignacio
  • Alan Felipe Ovalle Hernández Hospital Universitario de San Ignacio


Palabras clave:

antiespasmódicos, síndrome de intestino irritable, bromuro de pinaverio, bromuro de otilonio, mebeverina, trimebutina


El uso de los antiespasmódicos forma parte de la piedra angular del tratamiento en el síndrome de intestino irritable (SII), independientemente del subtipo. Consideramos relevante hacer una revisión de los medicamentos antiespasmódicos disponibles actualmente en Colombia, los cuales son usados crónicamente, de manera frecuente, en esta enfermedad.


Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Valeria Atenea Costa, Hospital Universitario San Ignacio



Areas  de  interes : VCE/enteroscopia/CPRE/ fisiologia  digestiva

Alan Felipe Ovalle Hernández, Hospital Universitario de San Ignacio

Fellow de segundo año, unidad de gastroenterología, Hospital Universitario San Ignacio. Pontificia Universidad Javeriana, Bogotá, Colombia.

Referencias bibliográficas

Ford AC, Moayyedi P, Chey WD, Harris LA, Lacy BE, Saito YA, et al. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2018 Jun;113(Suppl 2):1-18.

Annaházi A, Róka R, Rosztóczy A, Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014 May 28;20(20):6031-43.

Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel Disorders. Gastroenterology. 2016 May 1;150(6):1393-1407.e5.

Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006 Apr;130(5):1480-91.

Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA, Gutiérrez-Udave R, Maldonado-Garza HJ, Bosques-Padilla FJ. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex. 2012 Apr-Jun;77(2):82-90.

Janssen HA, Borghouts JA, Muris JW, Metsemakers JF, Koes BW, Knottnerus JA. Health status and management of chronic non-specific abdominal complaints in general practice. Br J Gen Pract. 2000 May;50(454):375-9.

Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008 Nov 13;337:a2313.

Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001 Mar;15(3):355-61.

Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ. 1997 Mar 15;314(7083):779-82.

Fichna J, Storr MA. Brain-Gut Interactions in IBS. Front Pharmacol. 2012 Jul 5;3:127.

Levy RL, Olden KW, Naliboff BD, Bradley LA, Francisconi C, Drossman DA, Creed F. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology. 2006 Apr;130(5):1447-58.

Bouin M, Plourde V, Boivin M, Riberdy M, Lupien F, Laganière M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology. 2002 Jun;122(7):1771-7.

Gecse K, Róka R, Ferrier L, Leveque M, Eutamene H, Cartier C, et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut. 2008 May;57(5):591-9.

Annaházi A, Ferrier L, Bézirard V, Lévêque M, Eutamène H, Ait-Belgnaoui A, et al. Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS. Am J Gastroenterol. 2013 Aug;108(8):1322-31.

Ahn JY, Lee KH, Choi CH, Kim JW, Lee HW, Kim JW, et al. Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis. Dig Dis Sci. 2014 May;59(5):1001-11.

Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004 Mar;126(3):693-702.

Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 2003 Dec;125(6):1651-9.

Lind CD. Motility disorders in the irritable bowel syndrome. Gastroenterol Clin North Am. 1991 Jun;20(2):279-95.

Clavé P. Treatment of IBS-D with 5-HT3 receptor antagonists vs spasmolytic agents: similar therapeutical effects from heterogeneous pharmacological targets. Neurogastroenterol Motil. 2011 Dec;23(12):1051-5.

Kanazawa M, Palsson OS, Thiwan SI, Turner MJ, van Tilburg MA, Gangarosa LM, et al. Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. Am J Gastroenterol. 2008 Oct;103(10):2550-61.

Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev. 2005 Dec;57(4):411-25.

Kochegarov AA. Pharmacological modulators of voltage-gated calcium channels and their therapeutical application. Cell Calcium. 2003 Mar;33(3):145-62.

Nowycky MC, Fox AP, Tsien RW. Three types of neuronal calcium channel with different calcium agonist sensitivity. Nature. 1985 Aug 1-7;316(6027):440-3.

Prior A, Harris SR, Whorwell PJ. Reduction of colonic motility by intravenous nicardipine in irritable bowel syndrome. Gut. 1987 Dec;28(12):1609-12.

Camilleri M, Boeckxstaens G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut. 2017 May;66(5):966-974.

Evangelista S, Cochet P, Bromet N, Criscuoli M, Maggi CA. A distribution study with (14)C-otilonium bromide in the rat: evidence for selective tropism for large intestine after oral administration. Drug Metab Dispos. 2000 Jun;28(6):643-7.

Evangelista S, Giachetti A, Chapelain B, Neliat G, Maggi CA. Receptor binding profile of Otilonium bromide. Pharmacol Res. 1998 Aug;38(2):111-7.

Boeckxstaens G, Corazziari ES, Mearin F, Tack J. IBS and the role of otilonium bromide. Int J Colorectal Dis. 2013 Mar;28(3):295-304.

Clavé P, Acalovschi M, Triantafillidis JK, Uspensky YP, Kalayci C, Shee V, et al. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2011 Aug;34(4):432-42.

D’Arienzo A. D’Agostino L. L’ottilonio bromuro nel trattamento della sindrome del colon irritabile. Rass Int Clin Ter. 1980;60:649-56.

Glende M, Morselli-Labate AM, Battaglia G, Evangelista S. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2002 Dec;14(12):1331-8.

Baldi F, Corinaldesi R, Ferrarini F, et al. Clinical and functional evaluation of octilonium bromide in the treatment of irritable bowel syndrome: a double-blind controlled trial. Clin Trials J. 1983;20:77-88.

Castiglione F, Daniele B, Mazzacca G. Therapeutic strategy for the irritable bowel syndrome. Ital J Gastroenterol. 1991 Nov;23(8 Suppl 1):53-5.

Christen MM-O, Tassignon J-P. Pinaverium bromide: A calcium channel blocker acting selectively on the gastrointestinal tract. Drug Dev Res. 1989 Jan 1;18(2):101-12.

Evangelista S. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Curr Pharm Des. 2004;10(28):3561-8.

Malysz J, Farraway LA, Christen MO, Huizinga JD. Pinaverium acts as L-type calcium channel blocker on smooth muscle of colon. Can J Physiol Pharmacol. 1997 Aug;75(8):969-75.

Boyer JC, Magous R, Christen MO, Balmes JL, Bali JP. Contraction of human colonic circular smooth muscle cells is inhibited by the calcium channel blocker pinaverium bromide. Cell Calcium. 2001 Jun;29(6):429-38.

Wittmann T, Fehér A, Rosztóczy A, Jánosi J. [Effectiveness of pinaverium bromide therapy on colonic motility disorders in irritable bowel syndrome]. Orv Hetil. 1999 Feb 28;140(9):469-73.

Zheng L, Lai Y, Lu W, Li B, Fan H, Yan Z, et al. Pinaverium Reduces Symptoms of Irritable Bowel Syndrome in a Multicenter, Randomized, Controlled Trial. Clin Gastroenterol Hepatol. 2015 Jul;13(7):1285-1292.e1.

Delmont J. Interet de l’adjonction d’un antispasmodique musculotrope au traitement des constipations douloureuses des colopathies fonctionnelles par le son. Med Chir Dig. 1981;10:365-70.

Levy C, Charbonnier A, Cachin M. [Pinaverium bromide and functional colonic disease (double-blind study]. Sem Hop Ther. 1977 Sep-Oct;53(7-8):372-4.

Virat J, Hueber D. Colopathy pain and dicetel. Prat Med. 1987;43:32-34.

Hussain Z, Jung DH, Lee YJ, Park H. The Effect of Trimebutine on the Overlap Syndrome Model of Guinea Pigs. J Neurogastroenterol Motil. 2018 Oct 1;24(4):669-675.

Kang SH, Jeen YT, Koo JS, Koo YS, Kim KO, Kim YS, et al. [Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome: multicenter randomized double-blind non-inferiority clinical study]. Korean J Gastroenterol. 2013 Nov;62(5):278-87.

Trimebutine Maleate and Pinaverium Bromide for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Nov 30.



Cómo citar

Costa, V. A., & Ovalle Hernández, A. F. (2019). Rol de los antiespasmódicos en el manejo del síndrome de intestino irritable. Revista Colombiana De Gastroenterología, 34(3), 269–276.



Revisión de tema


Crossref Cited-by logo
QR Code
Estadísticas de artículo
Vistas de resúmenes
Vistas de PDF
Descargas de PDF
Vistas de HTML
Otras vistas